Belgian Body Hits Out At Roche For Delaying Biosimilar Competition

Competition Authority Cites ‘Exclusionary Practices’ Over Rituximab And Trastuzumab

 
• By Dave Wallace
  
The BCA says Roche blocked biosimilars from the Belgian market (Shutterstock)

More from Generics Bulletin

More from Policy & Regulation